The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1308
March 23, 2009
View Complete Issue         Table of Contents 2019 
Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
March 23, 2009 (Issue: 1308)
The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for treating and maintaining healing of erosive esophagitis and for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis
Article code: 1308a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.